The document discusses a webinar that took place on July 8th, 2014 about Alzheimer's disease. It notes that gene variants with the highest functional impact may not necessarily show the strongest association with disease risk. It also mentions that cerebrospinal fluid TREM2 levels could be a better biomarker than plasma levels and questions whether any other variants could affect CSF TREM2 levels or if different TREM2 alternative transcripts play a role in its function and pathogenesis.